Congress locks in drug discounts for hospitals, blocks pharma workarounds
S. 2372 — 340B PATIENTS Act of 2025 · Filed by Peter Welch (D-VT) · 2 cosponsors · Introduced Jul 22, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill clarifies that pharmaceutical manufacturers participating in the 340B drug discount program must offer discounted prices to covered entities (hospitals, clinics, health centers) regardless of how or where those drugs are dispensed—including through contract pharmacies. It prohibits manufacturers from imposing conditions that restrict where drugs can be delivered, how they can be purchased, or what data must be reported, and establishes civil penalties up to $2 million per day for violations.
Why we flagged it
The bill's core function is to clarify and enforce existing 340B program rights for covered entities and patients, preventing manufacturers from circumventing the discount program through contractual restrictions. It is fundamentally a patient-access and program-integrity measure, not a price-control or subsidy mechanism.
What the text implies
- Manufacturers may face significant compliance costs and legal exposure if they have been conditioning 340B discounts on dispensing restrictions; the $2M/day penalty creates strong incentive to cease such practices immediately.
- Contract pharmacies—particularly specialty and mail-order pharmacies—gain explicit legal protection to dispense 340B drugs without manufacturer interference, potentially expanding their market share in specialty drug distribution.
- The bill does not cap or reduce the discount percentage itself; it only prevents manufacturers from blocking the discount's use through contract pharmacies, leaving pricing negotiations unchanged.
- Covered entities gain clearer authority to use 340B savings flexibly across their service lines, but the bill does not mandate transparency about how those savings are deployed or require reinvestment in patient care.
- The 180-day regulatory timeline for enforcement standards and violation claims processes may create a gap period during which manufacturers' compliance obligations are unclear, potentially delaying enforcement.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill protects patients' access to discounted specialty drugs by preventing manufacturers from blocking covered entities' use of contract pharmacies, which are often the only way to reach patients needing expensive treatments for cancer, arthritis, and other serious conditions. It strengthens enforcement against manufacturer overreach without imposing new costs on patients or restricting their care options.
Who stands to gain
- covered entities (hospitals, clinics, health centers)
- contract pharmacies (specialty and mail-order)
- patients requiring specialty drugs
Named in the bill
Section 340B of the Public Health Service Act, covered entities, drug manufacturers, contract pharmacies, Secretary of Health and Human Services, Medicare Part D, Medicaid, specialty drugs
Where it stands
2 cosponsors: 2 Democrats.
- Jul 22, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Jul 22, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
9 lobbying clients named this bill on 12 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $6,380,651 in lobbying spend. A filing names 16 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 89% of bills with at least one filing.
Peter Welch, the sponsor, reported $44,000 in PAC receipts in the 2026 cycle.
- American Hospital Association — $4,470,000 on 1 filing
- American Society of Health-system Pharmacists — $510,000 on 2 filings
- Lundbeck LLC — $350,000 on 2 filings
- National Association of Chain Drug Stores — $290,000 on 1 filing
- Catholic Health Association of the United States — $240,651 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (8,019 characters) on Aug 12, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress locks in drug discounts for hospitals, blocks pharma workarounds” QuorumCivic. https://share.quorumcivic.app/bill/119/s2372 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.